Table 1.
The half maximal inhibitory concentration (IC50) in human ovarian cancer cells
| Paclitaxel (nM) | Docetaxel (nM) | Epirubicin (nM) | Doxorubicin (nM) | Carboplatin (uM) | |
|---|---|---|---|---|---|
| TOV21G N | 1.31 ± 0.75 | 0.17 ± 4.43 | 6.30 ± 1.90 | 0.02 ± 1.01 | 17.99 ± 1.27 |
| TOV21G R | 44.64 ± 15.41 (34) | 10.73 ± 1.28 (63) | 20.06 ± 1.48 (3) | 9.90 ± 1.72 (495) | 0.59 ± 4.64 |
| TOV112D N | 1.49 ± 1.40 | 0.86 ± 1.50 | 9.60 ± 1.10 | 11.19 ± 1.11 | 80.81 ± 1.08 |
| TOV112D R | 28.26 ± 1.06 (19) | 13.91 ± 1.11 (16) | 34.78 ± 1.10 (3.6) | 30.16 ± 1.09 (3) | 140.0 ± 1.45 (2) |
| COV504 N | 1.91 ± 1.85 | 0.30 ± 3.37 | 31.56 ± 1.48 | 47.58 ± 1.81 | 103.68 ± 1.14 |
| COV504 R | 75.51 ± 27.44 (40) | 23.08 ± 1.25 (77) | 290.33 ± 2.20 (9) | 250.58 ± 2.50 (5) | 35.16 ± 1.35 |
The IC50 in both native (N) and drug resistant (R) ovarian cancer cell lines were determined by incremental and continuous exposure to drug. Drug resistance is clearly defined in all subtypes and most evident in the epithelial serous cell line, represented by COV504 for both taxanes and anthracyclines (± standard deviation, average of 3 independent experiments). The resistance factor is shown in parentheses and highlights drug resistance (resistant IC50/native IC50) for each cell line pair